April 2026
Cannabis
What April 2026's 9 new studies found, synthesized from the papers below. All Cannabis research →
The synthesis
Synthesized from 9 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Cannabis, marijuana, THC, tetrahydrocannabinol, then ranked by relevance.
Research published in April 2026 on cannabis covered a wide range of topics, from pharmacokinetics and therapeutic potential to psychiatric risks and public health interventions. Findings were mixed: while some studies reported potential benefits (e.g., anti-inflammatory effects in HIV, enhanced pain relief with a sigma1 antagonist), others highlighted risks (e.g., increased schizophrenia likelihood, altered reward processing). The evidence is largely preliminary or observational, with small samples or animal models, and no single overarching conclusion about cannabis effects can be drawn.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Pharmacokinetic study of delta-8-tetrahydrocannabinol in male rats using a validated bioanalytical method. 2026 | preclinical pharmacokinetic study | Unclear | Oral delta-8-THC has very low bioavailability (3.0%) and extensive tissue distribution, with clearance exceeding hepatic blood flow. | |
| A Systematic Review of Clinical Phenomenology, Differential Diagnosis and Prognostic Outcomes of Substance-Induced Psychotic Disorders. 2026 | systematic review | 80000 | Supports | Cannabis-induced psychosis is characterized by prominent positive symptoms and elevated affective/anxiety features, with transition rates to schizophrenia spectrum disorders ranging from 36% to 46%. |
| Regular cannabis use is associated with altered neural and behavioural responses during anticipation and feedback of monetary reward and loss 2026 | observational cohort | Mixed | Regular cannabis users exhibit altered neural correlates of reward processing during anticipation and outcome, but no differences in behavioral performance on the Monetary Incentive Delay Task compared with non-users. | |
| Classic psychedelic and cannabis use among U.S. cancer survivors aged ≥ 50 years: nationally representative estimates by cancer type/site. 2026 | cross-sectional survey analysis | 63959 | Mixed | Lifetime cannabis and classic psychedelic use among older adults showed modest differences between cancer survivors and those without cancer, with lower psychedelic and co-use in survivors during 2015-2019 but no significant differences by 2021-2022. |
| Cannabis use by people with HIV is associated with an anti-inflammatory immunometabolic phenotype in monocyte-derived macrophages. 2026 | cohort study | 83 | Supports | Daily cannabis use in people with HIV was associated with less global neurocognitive deficits and an anti-inflammatory immunometabolic phenotype in monocyte-derived macrophages. |
| Envisioning Cannabinoid CB1 Receptor Biased Signaling as a Therapeutic Target for Schizophrenia. 2026 | review | Supports | Argues that cannabis use dose-dependently increases the likelihood of a schizophrenia diagnosis, acutely exacerbates symptoms, and worsens long-term prognosis, and that CB1R-targeted treatments may be effective for schizophrenia, especially with comorbid cannabis use. | |
| Marcus Clarke’s “Cannabis Indica” and Altered States of Consciousness in 19th-Century Australian Mass Media 2026 | historical analysis | Unclear | Argues that Marcus Clarke's story 'Cannabis Indica' is a literary experiment that gothicises drug taking and adapts colonial understandings of the drug to explore colonial consciousness and the duality of rational and irrational thought. | |
| Perceptions of Delta-8 THC and the Impact of a Brief Educational Video Intervention for College Students. 2026 | randomized controlled trial | 120 | Supports | The educational video increased knowledge about delta-8 THC and lowered intentions to use it among students with prior but not recent use. |
| The Sigma1 receptor antagonist CM304 potentiates the antinociceptive effects of the cannabinoid receptor agonist delta9-tetrahydrocannabinol in rats and mice. 2026 | observational cohort | Supports | The sigma1 receptor antagonist CM304 potentiates the antinociceptive effects of THC without potentiating its adverse effects such as hypolocomotion or THC-like discriminative stimulus effects. |
Oral delta-8-THC has very low bioavailability (3.0%) and extensive tissue distribution, with clearance exceeding hepatic blood flow.
preclinical pharmacokinetic study
Cannabis-induced psychosis is characterized by prominent positive symptoms and elevated affective/anxiety features, with transition rates to schizophrenia spectrum disorders ranging from 36% to 46%.
systematic review Sample size: 80000
Regular cannabis users exhibit altered neural correlates of reward processing during anticipation and outcome, but no differences in behavioral performance on the Monetary Incentive Delay Task compared with non-users.
observational cohort
Lifetime cannabis and classic psychedelic use among older adults showed modest differences between cancer survivors and those without cancer, with lower psychedelic and co-use in survivors during 2015-2019 but no significant differences by 2021-2022.
cross-sectional survey analysis Sample size: 63959
Daily cannabis use in people with HIV was associated with less global neurocognitive deficits and an anti-inflammatory immunometabolic phenotype in monocyte-derived macrophages.
cohort study Sample size: 83
Argues that cannabis use dose-dependently increases the likelihood of a schizophrenia diagnosis, acutely exacerbates symptoms, and worsens long-term prognosis, and that CB1R-targeted treatments may be effective for schizophrenia, especially with comorbid cannabis use.
review
Argues that Marcus Clarke's story 'Cannabis Indica' is a literary experiment that gothicises drug taking and adapts colonial understandings of the drug to explore colonial consciousness and the duality of rational and irrational thought.
historical analysis
The educational video increased knowledge about delta-8 THC and lowered intentions to use it among students with prior but not recent use.
randomized controlled trial Sample size: 120
The sigma1 receptor antagonist CM304 potentiates the antinociceptive effects of THC without potentiating its adverse effects such as hypolocomotion or THC-like discriminative stimulus effects.
observational cohort
Points of agreement
- Cannabis use is associated with increased risk of psychosis and schizophrenia, with dose-dependent effects.
- Cannabis may have therapeutic potential in certain contexts, such as reducing neuroinflammation in HIV and enhancing pain relief when combined with other agents.
- Educational interventions can increase knowledge about cannabis products and reduce intentions to use them.
Conflicts
- Some studies report beneficial effects of cannabis (e.g., anti-inflammatory, neuroprotective), while others highlight risks (e.g., psychosis, altered reward processing).
- Findings on reward processing show neural alterations but no behavioral differences, suggesting a disconnect between neural and behavioral measures.
Gaps
- Most studies are preclinical, observational, or cross-sectional, limiting causal inference.
- Long-term durability of effects (e.g., educational intervention, pharmacokinetic parameters) is not assessed.
- Sample sizes are often small (e.g., 83 in HIV cohort) or not reported, and populations are limited (e.g., rats, college students, older adults).
- Dose-response relationships and sex differences are not fully explored in many studies.
- The clinical significance of neural alterations in reward processing remains unclear.